Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 4/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13921182 | 1.00 | CYP4F2 (0.51) | CYP4F2CYP4A11CYP4Z1CTSKCYP1A2 | |
| SCHEMBL25534610 | 0.88 | SMN1; SMN2 (0.47) | CYP4Z1CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4498506 | 0.85 | CTSK (0.47) | CTSKCTSSCA2 | |
| SCHEMBL13921181 | 0.85 | CTSK (0.47) | CTSKCTSSCA2 | |
| SCHEMBL5914021 | 0.81 | CA2 (0.46) | CTSKHTTACACBACACACTSS | |
| SCHEMBL4490823 | 0.81 | CA2 (0.46) | CTSKHTTACACBACACACTSS | |
| SCHEMBL24675580 | 0.81 | ACACB (0.52) | CTSKACACBACACA | |
| SCHEMBL30916868 | 0.81 | ACACB (0.52) | CTSKACACBACACA | |
| SCHEMBL4495406 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1CTSKCA2 | |
| SCHEMBL17524451 | 0.80 | NAMPT (0.53) | CTSKCYP1A2HTTACACBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504403-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1716150-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1716150-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MUSK, MAPT | CYP4F2 3007/4885CYP4A11 1705/4885CYP4Z1 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.